
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New research suggests that higher levels of sun exposure during childhood and early adolescence and greater actinic damage are associated with a reduced risk of developing multiple sclerosis.